554 related articles for article (PubMed ID: 18336964)
1. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
2. Neural progenitor cell lines inhibit rat tumor growth in vivo.
Staflin K; Honeth G; Kalliomäki S; Kjellman C; Edvardsen K; Lindvall M
Cancer Res; 2004 Aug; 64(15):5347-54. PubMed ID: 15289341
[TBL] [Abstract][Full Text] [Related]
3. Cytokine gene therapy of gliomas: effective induction of therapeutic immunity to intracranial tumors by peripheral immunization with interleukin-4 transduced glioma cells.
Okada H; Villa L; Attanucci J; Erff M; Fellows WK; Lotze MT; Pollack IF; Chambers WH
Gene Ther; 2001 Aug; 8(15):1157-66. PubMed ID: 11509946
[TBL] [Abstract][Full Text] [Related]
4. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
5. B7.1 expression by the weakly immunogenic F98 rat glioma does not enhance immunogenicity.
Paul DB; Barth RF; Yang W; Shen GH; Kim J; Triozzi PL
Gene Ther; 2000 Jun; 7(12):993-9. PubMed ID: 10871746
[TBL] [Abstract][Full Text] [Related]
6. Eradication of rat malignant gliomas by retroviral-mediated, in vivo delivery of the interleukin 4 gene.
Benedetti S; Bruzzone MG; Pollo B; DiMeco F; Magrassi L; Pirola B; Cirenei N; Colombo MP; Finocchiaro G
Cancer Res; 1999 Feb; 59(3):645-52. PubMed ID: 9973213
[TBL] [Abstract][Full Text] [Related]
7. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
8. Immunological responsiveness to interleukin-2-producing brain tumors can be restored by concurrent subcutaneous transplantation of the same tumors.
Iwadate Y; Tagawa M; Namba H; Oga M; Kawamura K; Tasaki K; Sakiyama S; Yamaura A
Cancer Gene Ther; 2000 Sep; 7(9):1263-9. PubMed ID: 11023199
[TBL] [Abstract][Full Text] [Related]
9. Application of interleukin-2-secreting syngeneic/allogeneic fibroblasts in the treatment of primary and metastatic brain tumors.
Lichtor T; Glick RP; Tarlock K; Moffett S; Mouw E; Cohen EP
Cancer Gene Ther; 2002 May; 9(5):464-9. PubMed ID: 11961669
[TBL] [Abstract][Full Text] [Related]
10. Immunogene therapy as a treatment for malignant brain tumors in young mice.
Glick RP; Lichtor T; Lin H; Tarlock K; Cohen EP
J Neurosurg; 2006 Jul; 105(1 Suppl):65-70. PubMed ID: 16871873
[TBL] [Abstract][Full Text] [Related]
11. Development of a xenograft glioma model in mouse brain.
Kaye AH; Morstyn G; Gardner I; Pyke K
Cancer Res; 1986 Mar; 46(3):1367-73. PubMed ID: 3943101
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of particulate systems supporting tumor cell fractions in a preventive vaccination against intracranial rat glioma.
Sapin A; Clavreul A; Garcion E; Benoit JP; Menei P
J Neurosurg; 2006 Nov; 105(5):745-52. PubMed ID: 17121138
[TBL] [Abstract][Full Text] [Related]
13. Generation of an effective anti-tumor immunity after immunization with xenogeneic antigens.
Sioud M; Sørensen D
Eur J Immunol; 2003 Jan; 33(1):38-45. PubMed ID: 12594830
[TBL] [Abstract][Full Text] [Related]
14. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen.
Auf G; Carpentier AF; Chen L; Le Clanche C; Delattre JY
Clin Cancer Res; 2001 Nov; 7(11):3540-3. PubMed ID: 11705874
[TBL] [Abstract][Full Text] [Related]
15. Treatment of malignant gliomas with mitoxantrone-loaded poly (lactide-co-glycolide) microspheres.
Yemisci M; Bozdag S; Cetin M; Söylemezoglu F; Capan Y; Dalkara T; Vural I
Neurosurgery; 2006 Dec; 59(6):1296-302; discussion 1302-3. PubMed ID: 17277693
[TBL] [Abstract][Full Text] [Related]
16. Prevention of tumors in rats by cross-protective immunization.
Fish DC; Bare AL; Djurickovic DB; Huebner RJ
J Natl Cancer Inst; 1981 Nov; 67(5):1041-51. PubMed ID: 6946246
[TBL] [Abstract][Full Text] [Related]
17. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
18. Spontaneous regression of experimental gliomas--an immunohistochemical and MRI study of the C6 glioma spheroid implantation model.
Vince GH; Bendszus M; Schweitzer T; Goldbrunner RH; Hildebrandt S; Tilgner J; Klein R; Solymosi L; Christian Tonn J; Roosen K
Exp Neurol; 2004 Dec; 190(2):478-85. PubMed ID: 15530886
[TBL] [Abstract][Full Text] [Related]
19. Glioma-specific antigens for immune tumor therapy.
Skog J
Expert Rev Vaccines; 2006 Dec; 5(6):793-802. PubMed ID: 17184218
[TBL] [Abstract][Full Text] [Related]
20. Modulation of tumor immunogenicity of rat glioma cells by s-Myc expression: eradication of rat gliomas in vivo.
Asai A; Miyagi Y; Hashimoto H; Lee SH; Mishima K; Sugiyama A; Tanaka H; Mochizuki T; Yasuda T; Kuchino Y
Cell Growth Differ; 1994 Nov; 5(11):1153-8. PubMed ID: 7848917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
